Part,  Chapter, Paragraph

 1   II,     5. 15.Acr|          Myopathies~COMP~Committee of Orphan Medicinal Products~EMEA~
 2   II,     5. 15.Acr|     Organization of Rare Disorders~OD~Orphan Drugs~RD~Rare Diseases~ ~
 3   II,     5. 15.  3|               available data concerns Orphan Drugs (OD), drugs developed
 4   II,     5. 15.  3|     independent study on the price of orphan drugs (OD). The study, conducted
 5   II,     5. 15.  3|        Alcimed, looks at the price of orphan drugs authorised in the
 6   II,     5. 15.  3|                 Currently over 40 new orphan medicinal products are on
 7   II,     5. 15.  3|       collected data on the access to orphan drugs in Europe (dates of
 8   II,     5. 15.  3|          market is not respected, and orphan drugs are made available
 9   II,     5. 15.  4|        Council of 16 December 1999 on orphan medicinal products sets
10   II,     5. 15.  4|              sets up the criteria for orphan designation in the EU and
11   II,     5. 15.  4|         implementing the criteria for orphan designation and defining
12   II,     5. 15.  4|             Regulation No 141/2000 on Orphan Medicinal Products in the
13   II,     5. 15.  4|            support the development of Orphan Medicinal Products and adapt
14   II,     5. 15.  4|              In 2000, a Committee for Orphan Medicinal Products (COMP)
15   II,     5. 15.  4|         studying the applications for orphan designation, for giving
16   II,     5. 15.  4|        opinions on the designation of orphan medicinal products, and
17   II,     5. 15.  4|          Commission in discussions on orphan drugs.~ ~DG Public Health
18   II,     5. 15.  6|              ALCIMED (2004): Study on Orphan Drugs. Published 16/11/04.
19   II,     5. 15.  6|          death? A call for a national orphan drug review policy. CMAJ.
20   II,     5. 15.  6|               of developing and using orphan medicinal products. Br J
21   II,     5. 15.  6|          economic challenges posed by orphan drugs. Int J Technol Assess
22   II,     5. 15.  6|       Development and Availability of Orphan Medicinal Products, Revision
23   II,     5. 15.  6|           Haffner ME (2006): Adopting orphan drugs -- two dozen years
24   II,     5. 15.  6|          health budgets for expensive orphan drugs: Gaucher disease in
25   II,     5. 15.  6|         Claxton K, Tsuchiya A (2005): Orphan drugs and the NHS: should
26   II,     5. 15.  6|         database of rare diseases and orphan drugs. Available at: htt et~
27   II,     5. 15.  6|               S, Leufkens HGM (2004): Orphan Diseases in “Priority Medicines
28   II,     5. 15.  6|          studies on rare diseases and orphan drugs. J Intern Med. 2006;
29  III,    10.  2.  4|         Database of Rare Diseases and Orphan Drugs~PHG~Public Health
30   IV,    12.  1    |     advertising and the protection of orphan medicinal products~Information~
31  Key,   Ap5.  0.  0| organophosphorus~orofacial~oropharinx~orphan~osteoarthritis~osteoporosis~